“EBITDA for Q1 FY26 was reported at Rs 39.08 crore as compared to EBITDA of Rs 33.14 crore in Q1 FY25, growth of 17.92% Y-o-Y,” the statement said.
The company is targeting a revenue of Rs 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets, Lincoln Pharmaceuticals Managing Director Mahendra Patel said.
